CL2015002609A1 - 2-azabiciclos sustituidos y su uso como moduladores de rectores de orexina. - Google Patents

2-azabiciclos sustituidos y su uso como moduladores de rectores de orexina.

Info

Publication number
CL2015002609A1
CL2015002609A1 CL2015002609A CL2015002609A CL2015002609A1 CL 2015002609 A1 CL2015002609 A1 CL 2015002609A1 CL 2015002609 A CL2015002609 A CL 2015002609A CL 2015002609 A CL2015002609 A CL 2015002609A CL 2015002609 A1 CL2015002609 A1 CL 2015002609A1
Authority
CL
Chile
Prior art keywords
modulators
rector
orexin
substituted
azabicycles
Prior art date
Application number
CL2015002609A
Other languages
English (en)
Inventor
Brock T Shireman
Christine F Gelin
Terry P Lebold
Jeannie M Ziff
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2015002609A1 publication Critical patent/CL2015002609A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

COMPUESTOS DERIVADOS DE 7-AZABICICLOS SUSTITUIDOS, MODULADORES DEL RECEPTOR DE OREXINA; COMPOSICION FARMACEUTICA; Y SU USO EN EL TRATAMIENTO DE UN TRASTORNO DE CICLO SUEÑO-VIGILIA, INSOMNIO, ANSIEDAD, FIBROMIALGIA, DEPRESION, ENF. PARKINSON, ENTRE. OTRAS
CL2015002609A 2013-03-13 2015-09-11 2-azabiciclos sustituidos y su uso como moduladores de rectores de orexina. CL2015002609A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361780378P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
CL2015002609A1 true CL2015002609A1 (es) 2016-03-28

Family

ID=50487148

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002609A CL2015002609A1 (es) 2013-03-13 2015-09-11 2-azabiciclos sustituidos y su uso como moduladores de rectores de orexina.

Country Status (38)

Country Link
US (5) US9611277B2 (es)
EP (4) EP3622956B9 (es)
JP (1) JP6275815B2 (es)
KR (1) KR102209424B1 (es)
CN (3) CN105308048B (es)
AR (1) AR095423A1 (es)
AU (2) AU2014248680B2 (es)
BR (1) BR112015022294B1 (es)
CA (1) CA2904618C (es)
CL (1) CL2015002609A1 (es)
CR (2) CR20210523A (es)
CY (3) CY1120024T1 (es)
DK (2) DK2970314T3 (es)
EA (1) EA029276B1 (es)
ES (3) ES2950032T3 (es)
HK (1) HK1219725A1 (es)
HR (3) HRP20230633T1 (es)
HU (3) HUE063608T2 (es)
IL (2) IL240466B (es)
JO (1) JOP20140092B1 (es)
LT (2) LT2970314T (es)
ME (2) ME03011B (es)
MX (2) MX361529B (es)
MY (1) MY183725A (es)
NI (1) NI201500130A (es)
NO (1) NO3107630T3 (es)
PE (1) PE20151599A1 (es)
PH (1) PH12015501929B1 (es)
PL (3) PL2970314T3 (es)
PT (2) PT3363438T (es)
RS (3) RS56875B1 (es)
SG (1) SG11201507415QA (es)
SI (2) SI2970314T1 (es)
TW (1) TWI621618B (es)
UA (1) UA118669C2 (es)
UY (1) UY35409A (es)
WO (1) WO2014165070A1 (es)
ZA (1) ZA201507562B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2491038B1 (en) 2009-10-23 2016-04-06 Janssen Pharmaceutica N.V. Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP3569598A1 (en) 2011-11-17 2019-11-20 Dana Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
TWI621618B (zh) * 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
CA2941663C (en) * 2014-03-06 2020-02-18 Shanghai Haiyan Pharmaceutical Technology Co. Ltd Piperidine derivatives as orexin receptor antagonist
BR112017004742B1 (pt) * 2014-09-11 2022-11-29 Janssen Pharmaceutica Nv 2-azabiciclos substituídos e seu uso como moduladores de receptor de orexina
US9938276B2 (en) * 2014-12-19 2018-04-10 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
US10196383B2 (en) 2015-07-17 2019-02-05 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
JP6772251B2 (ja) * 2015-08-14 2020-10-21 シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． オレキシン受容体拮抗薬の化合物の結晶形およびその製造方法と使用
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
SG11201804223TA (en) 2015-11-23 2018-06-28 Sunshine Lake Pharma Co Ltd OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF
UA125873C2 (uk) 2016-03-10 2022-06-29 Янссен Фармацевтика Нв Спосіб лікування депресії з використанням антагоністів рецептора орексин-2
KR102269305B1 (ko) 2016-06-13 2021-06-25 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
EP3544971B1 (en) 2016-11-22 2022-07-06 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (cdk12) and uses thereof
CN110461328A (zh) 2017-03-28 2019-11-15 吉利德科学公司 治疗肝疾病的治疗组合
GB2558975B (en) * 2017-09-01 2019-01-23 Chronos Therapeutics Ltd Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
JP7391012B2 (ja) * 2017-09-01 2023-12-04 クロノス セラピューティクス リミテッド オレキシン受容体拮抗薬としての置換２－アザビシクロ［３．１．１］ヘプタンおよび２－アザビシクロ［３．２．１］オクタン誘導体
US20220073512A1 (en) * 2018-12-14 2022-03-10 Dana-Farber Cancer Institute, Inc. Pyrazolopyridine inhibitors of c-jun-n-terminal kinases and uses thereof
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674793A (en) 1967-03-29 1972-07-04 Sterling Drug Inc 6-hydroxy-2-azabicyclo(2.2.2)octan-3-ones and 2-azabicyclo(2.2.2.)octane-3,6-diones
US6505492B2 (en) 2001-04-11 2003-01-14 Bethlehem Steel Corporation Method and apparatus for forming deep-drawn articles
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
EP1594852A1 (en) 2003-02-07 2005-11-16 Ranbaxy Laboratories, Ltd. Oxazolidinone derivatives as antimicrobials
BRPI0407714A (pt) 2003-02-21 2006-02-14 Pharmacia & Up John Company Ll "exo-2r (+)-2-amino-7-azabiciclo[2.2.1]heptano-7-carboxilato de t-butila, intermediário, e processo para os preparar e isolar
AR058554A1 (es) 2005-12-20 2008-02-13 Novartis Ag Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5.
WO2008031550A2 (en) 2006-09-11 2008-03-20 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutanate receptors
ATE496043T1 (de) 2006-12-01 2011-02-15 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren
TW200833328A (en) 2006-12-28 2008-08-16 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
AU2008276057B2 (en) 2007-07-17 2013-01-31 Bristol-Myers Squibb Company Method for modulating GPR119 G protein-coupled receptor and selected compounds
KR101204213B1 (ko) 2007-12-21 2012-11-26 에프. 호프만-라 로슈 아게 오렉신 수용체 길항제로서의 헤테로아릴 유도체
CA2713184A1 (en) * 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[2.2.1]heptane derivatives
CA2722347A1 (en) 2008-04-30 2009-11-05 Actelion Pharmaceuticals Ltd Piperidine and pyrrolidine compounds
US8822480B2 (en) 2008-07-16 2014-09-02 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
EP2350061B1 (en) 2008-10-21 2013-08-14 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
CA2739916A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
WO2010063663A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
SG175026A1 (en) 2009-04-24 2011-11-28 Glaxo Group Ltd 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists
EP2491038B1 (en) 2009-10-23 2016-04-06 Janssen Pharmaceutica N.V. Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
AU2010313469A1 (en) 2009-10-29 2012-06-07 Merck Sharp & Dohme Corp. Bridged Bicyclic Piperidine Derivatives and methods of use thereof
US9301929B2 (en) 2009-11-24 2016-04-05 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
EP2512239A4 (en) 2009-12-14 2014-11-26 Inspire Pharmaceuticals Inc BROKEN BICYCLIC RHO-KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE
US8697691B2 (en) 2009-12-21 2014-04-15 Vanderbilt University Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2011159657A1 (en) 2010-06-18 2011-12-22 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US9546152B2 (en) 2012-10-23 2017-01-17 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-substituted-4-nitrile orexin receptor antagonists
EP2920171B1 (en) 2012-11-16 2018-08-29 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
CA2938719A1 (en) 2014-02-06 2015-08-13 Abbvie, Inc. 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
BR112017004742B1 (pt) 2014-09-11 2022-11-29 Janssen Pharmaceutica Nv 2-azabiciclos substituídos e seu uso como moduladores de receptor de orexina

Also Published As

Publication number Publication date
KR20150126694A (ko) 2015-11-12
PH12015501929A1 (en) 2016-01-04
CN110669052A (zh) 2020-01-10
PL2970314T3 (pl) 2018-05-30
MX361529B (es) 2018-12-07
EP2970314B1 (en) 2017-12-13
ES2659397T3 (es) 2018-03-15
EP4272824A2 (en) 2023-11-08
PE20151599A1 (es) 2015-11-12
MX368466B (es) 2019-10-03
BR112015022294A2 (pt) 2017-07-18
CN110669052B (zh) 2022-10-11
EP3363438A1 (en) 2018-08-22
PL3622956T3 (pl) 2023-09-18
US20170015651A1 (en) 2017-01-19
HUE047592T2 (hu) 2020-05-28
US9611277B2 (en) 2017-04-04
EP3363438B1 (en) 2019-09-18
AU2014248680A1 (en) 2015-08-27
CA2904618A1 (en) 2014-10-09
HUE036193T2 (hu) 2018-06-28
UA118669C2 (uk) 2019-02-25
RS56875B1 (sr) 2018-04-30
HRP20192032T1 (hr) 2020-02-07
US20140275118A1 (en) 2014-09-18
US10183953B2 (en) 2019-01-22
US9845333B2 (en) 2017-12-19
CN105308048A (zh) 2016-02-03
AU2018204835B2 (en) 2019-08-08
ME03011B (me) 2018-10-20
IL240466A0 (en) 2015-09-24
US20170204096A1 (en) 2017-07-20
NO3107630T3 (es) 2018-01-06
JOP20140092B1 (ar) 2021-08-17
PL3363438T3 (pl) 2020-02-28
ES2950032T3 (es) 2023-10-04
WO2014165070A1 (en) 2014-10-09
DK2970314T3 (en) 2018-02-26
RS64551B9 (sr) 2023-12-29
PT3363438T (pt) 2019-12-11
CR20150433A (es) 2015-10-26
HK1219725A1 (zh) 2017-04-13
JP2016512535A (ja) 2016-04-28
US8969352B2 (en) 2015-03-03
BR112015022294B1 (pt) 2022-09-13
CR20210523A (es) 2021-11-19
NI201500130A (es) 2015-11-30
EA029276B1 (ru) 2018-03-30
HRP20180303T1 (hr) 2018-03-23
EA201591703A1 (ru) 2016-02-29
EP2970314A1 (en) 2016-01-20
IL264606A (en) 2019-02-28
AR095423A1 (es) 2015-10-14
RS64551B1 (sr) 2023-10-31
AU2018204835A1 (en) 2018-07-19
EP3622956B9 (en) 2023-09-27
ZA201507562B (en) 2019-04-24
CY1122392T1 (el) 2021-01-27
CA2904618C (en) 2021-12-07
JP6275815B2 (ja) 2018-02-07
PT2970314T (pt) 2018-03-05
HRP20230633T1 (hr) 2023-09-29
IL240466B (en) 2019-03-31
EP3622956A1 (en) 2020-03-18
CY1126106T1 (el) 2023-11-15
LT2970314T (lt) 2018-02-12
TW201446757A (zh) 2014-12-16
US9447117B2 (en) 2016-09-20
MX2015011815A (es) 2016-11-07
SI3363438T1 (sl) 2019-11-29
HUE063608T2 (hu) 2024-01-28
KR102209424B1 (ko) 2021-01-29
US20160052939A1 (en) 2016-02-25
CY1120024T1 (el) 2018-12-12
SG11201507415QA (en) 2015-10-29
AU2014248680B2 (en) 2018-07-26
CN105308048B (zh) 2019-10-08
US20150174129A1 (en) 2015-06-25
TWI621618B (zh) 2018-04-21
UY35409A (es) 2014-09-30
ME03572B (me) 2020-07-20
ES2760564T3 (es) 2020-05-14
EP3622956B1 (en) 2023-06-07
LT3363438T (lt) 2019-11-11
EP3622956C0 (en) 2023-06-07
SI2970314T1 (en) 2018-02-28
RS59466B1 (sr) 2019-11-29
NZ710872A (en) 2020-10-30
CN108864093A (zh) 2018-11-23
PH12015501929B1 (en) 2016-01-04
MY183725A (en) 2021-03-10
DK3363438T3 (da) 2019-11-11
EP4272824A3 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
CL2015002609A1 (es) 2-azabiciclos sustituidos y su uso como moduladores de rectores de orexina.
CL2015002616A1 (es) 7-azabiciclos sustituidos y su uso como modulares del receptor de orexina.
CL2017001987A1 (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
SV2017005445A (es) Agonistas parciales del receptor de insulina
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
PH12016501763A1 (en) Multispecific antibodies
CL2016000922A1 (es) Derivados de anillo bicíclico fusionado piridilo como inhibidores fgfr4
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
PH12015501846A1 (en) Novel antibody conjugates and uses thereof
BR112015023752A2 (pt) complexos multiespecificos monovalentes e multivalentes e seus usos
UY35500A (es) Indazoles sustituidos con heteroarilo
UY36179A (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagón
AR101905A1 (es) Compuestos bicíclicos
ECSP14013164A (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide
NZ738538A (en) 6-amino-quinoline-3-carbonitrils as cot modulators
UY34610A (es) Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
TWD164982S (zh) 汽車用儀表板
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
UY34863A (es) Antagonistas de iap
PH12016500598A1 (en) Protoxin-ii variants and methods of use
GT201500012A (es) Derivados de carbamato/urea
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
TWD163873S (zh) 手錶
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso
UY34594A (es) Derivados heterocíclicos bicíclicos, su preparación y su aplicación en terapéutica